Latest news with #EmcurePharmaceuticalsLimited
Business Upturn
09-07-2025
- Business
- Business Upturn
Emcure's Sanand oncology facility clears US FDA inspection with zero observations
By Aditya Bhagchandani Published on July 9, 2025, 17:33 IST Emcure Pharmaceuticals Limited announced that its oncology manufacturing facility in Sanand, Ahmedabad has successfully cleared a Pre-Approval Inspection (PAI) conducted by the US Food and Drug Administration (US FDA) without any observations. In a regulatory filing on July 9, 2025, the company informed that the inspection was conducted between June 30 and July 8, 2025, and concluded without the issuance of a Form 483, indicating zero observations. The Sanand facility is located at GIDC, Taluka Sanand, Ahmedabad, Gujarat, and specializes in the production of oncology products for regulated markets. Emcure's Company Secretary & Compliance Officer, Chetan Sharma, signed the disclosure addressed to the National Stock Exchange of India and BSE Limited. The company stated that the outcome of the inspection reflects its commitment to maintaining global quality and compliance standards. For more details, visit: Disclaimer: The information provided in this article is based on the company's regulatory filing and is for informational purposes only. It does not constitute investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Insider
25-05-2025
- Business
- Business Insider
Jefferies Remains a Buy on Emcure Pharmaceuticals Limited (EMCURE)
In a report released on May 23, Alok Dalal from Jefferies maintained a Buy rating on Emcure Pharmaceuticals Limited (EMCURE – Research Report), with a price target of INR1,400.00. The company's shares closed last Friday at INR1,288.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Dalal is ranked #4967 out of 9536 analysts. The analyst consensus on Emcure Pharmaceuticals Limited is currently a Hold rating. The company has a one-year high of INR1,577.50 and a one-year low of INR890.00. Currently, Emcure Pharmaceuticals Limited has an average volume of 29.65K.
